ClassID:

96688

C07K5/06052 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms Val-amino acid

Recent Application in this class:
#1
20260098013
2026-04-09

Stereoisomer Conjugates of Dextrorphan

#2
20260062421
2026-03-05

NOVEL PROCESSES FOR PREPARING CAMPTOTHECIN DERIVATIVES

#3
20250296912
2025-09-25

AFFINITY ILLUDOFULVENE CONJUGATES

#4
20250135024
2025-05-01

Drug-Conjugates, Conjugation Methods, And Uses Thereof

#5
20250002595
2025-01-02

Anti-CD70 Antibody Drug Conjugates

#6
20240382612
2024-11-21

BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF

#7
20240285584
2024-08-29

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#8
20240165260
2024-05-23

CONJUGATES OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALTS THEREOF, AND COMPOUNDS USED IN PRODUCTION OF THE SAME OR SALTS THEREOF

#9
20240065990
2024-02-29

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

#10
20240042052
2024-02-08

PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDS

#11
20230390408
2023-12-07

LINKER COMPOUNDS COMPRISING AMIDE BONDS

#12
20230357259
2023-11-09

BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF

#13
20230295320
2023-09-21

Anti-CD70 antibody drug conjugates

#14
20230242572
2023-08-03

a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

#15
20230212113
2023-07-06

Affinity illudofulvene conjugates

#16
20230128167
2023-04-27

OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF

#17
20230091510
2023-03-23

ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS

#18
20230023537
2023-01-26

DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE

#19
20220249688
2022-08-11

Plant virus particles for delivery of antimitotic agents

#20
20220202777
2022-06-30

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#21
20220031858
2022-02-03

NOVEL LINKERS

#22
20210386693
2021-12-16

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

#23
20210316006
2021-10-14

PYRROLOBENZODIAZEPINE CONJUGATES

#24
20210308276
2021-10-07

Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates

#25
20210300867
2021-09-30

SELF-STABILIZING LINKER CONJUGATES

#26
20210261505
2021-08-26

Linker, Antibody-Drug Conjugate Including Same and Use Thereof

#27
20210187119
2021-06-24

Drug-conjugates, conjugation methods, and uses thereof

#28
20210163880
2021-06-03

BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES

#29
20210155583
2021-05-27

Affinity illudofulvene conjugates

#30
20210061923
2021-03-04

Bifunctional cytotoxic agents containing the CTI pharmacophore

#31
20210040081
2021-02-11

Indole derivatives as estrogen receptor degraders

#32
20210040039
2021-02-11

NMDA ANTAGONIST PRODRUGS

#33
20210008222
2021-01-14

Plant virus particles for delivery of antimitotic agents

#34
20200399203
2020-12-24

Prodrugs of fencamfamine

#35
20200360532
2020-11-19

Process for the preparation of drug linker compounds

#36
20200347075
2020-11-05

Bioactive molecule conjugate, preparation method and use thereof

#37
20200277647
2020-09-03

Chemiluminescent probes for imaging/detection of proteases

#38
20200253897
2020-08-13

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

#39
20200237637
2020-07-30

N-acyldipeptide derivatives and their uses

#40
20200085969
2020-03-19

Plant virus particles for delivery of antimitotic agents

#41
20200009086
2020-01-09

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

#42
20190389904
2019-12-26

MALT1 inhibitors and uses thereof

#43
20190343804
2019-11-14

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#44
20190338039
2019-11-07

Anti-CD70 antibody drug conjugates

#45
20190307890
2019-10-10

PYRROLOBENZODIAZEPINE CONJUGATES

#46
20190275101
2019-09-12

Structure of GII.4 norovirus protease—design of broad-spectrum protease inhibitors

#47
20190233471
2019-08-01

Cytotoxic tubulysin compounds for conjugation

#48
20190233408
2019-08-01

Indole derivatives as estrogen receptor degraders

#49
20190152914
2019-05-23

NMDA antagonist prodrugs

#50
20190127420
2019-05-02

Dipeptide analogs as TGF-beta inhibitors

#51
20190085024
2019-03-21

Alpha-Ketoamide Inhibitors Of Cysteine Proteases

#52
20190062748
2019-02-28

Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo

#53
20190047969
2019-02-14

Immunoproteasome inhibitor analogs

#54
20190023650
2019-01-24

Prodrugs of fencamfamine

#55
20190002484
2019-01-03

Delivery systems for controlled drug release

#56
20180346780
2018-12-06

Molecular gelators and uses thereof

#57
20180346435
2018-12-06

Tricyclic prodrugs

#58
20180303741
2018-10-25

Combination of N-acyldipeptide derivatives and retinol, and methods of use thereof

#59
20180251489
2018-09-06

MALT1 inhibitors and uses thereof

#60
20180243438
2018-08-30

Drug-conjugates, conjugation methods, and uses thereof

#61
20180228772
2018-08-16

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#62
20180207226
2018-07-26

Compositions and methods for inhibition of bacterial infections in human endocervix

#63
20180200384
2018-07-19

Plant virus particles for delivery of antimitotic agents

#64
20180170961
2018-06-21

Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient

#65
20180155392
2018-06-07

Cystargolide compounds and uses thereof

#66
20180154011
2018-06-07

SELF-STABILIZING LINKER CONJUGATES

#67
20180079781
2018-03-22

Benzodiazepine dimers, conjugates thereof, and methods of making and using

#68
20180057527
2018-03-01

Carbazole compound having anti-virus activity

#69
20180044376
2018-02-15

Method for preparing largazole analogs and uses thereof

#70
20180037581
2018-02-08

HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING

#71
20180037550
2018-02-08

NMDA antagonist prodrugs

#72
20170321187
2017-11-09

BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES

#73
20170247324
2017-08-31

ALDEHYDE CAPTURE LIGATION TECHNOLOGY FOR SYNTHESIS OF AMIDE BONDS

#74
20170239365
2017-08-24

Pyrrolobenzodiazepines and conjugates thereof

#75
20170233436
2017-08-17

Benzodiazepine dimers, conjugates thereof, and methods of making and using

#76
20170226155
2017-08-10

Smart Pro-Drugs of Serine Protease Inhibitors

#77
20170224759
2017-08-10

Compositions and methods for treating colorectal cancer

#78
20170196849
2017-07-13

HCV NS-3 serine protease inhibitors

#79
20170190737
2017-07-06

Macrocyclic inhibitors of flaviviridae viruses

#80
20170190736
2017-07-06

Antibody drug conjugates

#81
20170119841
2017-05-04

AMINO ACID SALTS OF UNSATURATED FATTY ACIDS

#82
20170119737
2017-05-04

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#83
20170119646
2017-05-04

N-acyldipeptide derivatives and their uses

#84
20170114092
2017-04-27

Selective caspase inhibitors and uses thereof

#85
20170095430
2017-04-06

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

#86
20170088813
2017-03-30

Biologically active C-terminal arginine-containing peptides

#87
20170015709
2017-01-19

Glycopeptide derivatives for the preservation and protection of biological materials and microorganisms

#88
20170015644
2017-01-19

Tricyclic prodrugs

#89
20170002041
2017-01-05

NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES

#90
20160375177
2016-12-29

Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing

#91
20160368911
2016-12-22

Benzothiophene derivatives as estrogen receptor inhibitors

#92
20160346402
2016-12-01

Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)

#93
20160340386
2016-11-24

Cytotoxic tubulysin compounds for conjugation

#94
20160271270
2016-09-22

Bifunctional cytotoxic agents containing the CTI pharmacophore

#95
20160271142
2016-09-22

Isoquinolidinobenzodiazepines

#96
20160263238
2016-09-15

Maytansinoid derivatives with peptide linker and conjugates thereof

#97
20160235711
2016-08-18

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#98
20160207915
2016-07-21

Prodrug derivatives of substituted triazolopyridines

#99
20160199510
2016-07-14

Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using

#100
20160194352
2016-07-07

AMORPHOUS FORMS OF DACLATASVIR DIHYDROCHLORIDE

#101
20160158307
2016-06-09

Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis

#102
20160145305
2016-05-26

Energy transfer within pi-conjugated peptide heterostructures in aqueous environments

#103
20160130299
2016-05-12

Tubulysin analogs and methods of making and use

#104
20160115147
2016-04-28

PRO-DRUG COMPOUNDS

#105
20160075735
2016-03-17

Cytotoxic and anti-mitotic compounds, and methods of using the same

#106
20160068788
2016-03-10

Liquid automatic dish washing detergent compositions

#107
20160067302
2016-03-10

Hepatitis C virus inhibitors

#108
20160045607
2016-02-18

Estrogen-related receptor alpha based protac compounds and associated methods of use

#109
20150367028
2015-12-24

Amphiphilic linear peptide/peptoid and hydrogel comprising the same

#110
20150353601
2015-12-10

Compounds for enzyme inhibition

#111
20150344521
2015-12-03

Macrocyclic inhibitors of flaviviridae viruses

#112
20150322108
2015-11-12

CRYSTALLINE POLYMORPHS

#113
20150320879
2015-11-12

SELF-STABILIZING LINKER CONJUGATES

#114
20150274774
2015-10-01

Macrocyclic inhibitors of flaviviridae viruses

#115
20150274737
2015-10-01

Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation

#116
20150250846
2015-09-10

N-acyldipeptide derivatives and their uses

#117
20150246136
2015-09-03

NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME

#118
20150246091
2015-09-03

Combinations of a caspase inhibitor and an antiviral agent

#119
20150232504
2015-08-20

Aldehyde capture ligation technology for synthesis of amide bonds

#120
20150225455
2015-08-13

Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same

#121
20150183822
2015-07-02

ANGIOTENSIN-CONVERTING-ENZYME INHIBITING DIPEPTIDE

#122
20150175654
2015-06-25

Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient

#123
20150166489
2015-06-18

Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof

#124
20150165063
2015-06-18

1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment

#125
20150158909
2015-06-11

ANTI-VIRAL COMPOUNDS

#126
20150158869
2015-06-11

Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates

#127
20150157736
2015-06-11

Hydrazinyl-pyrrolo compounds and methods for producing a conjugate

#128
20150148395
2015-05-28

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#129
20150141624
2015-05-21

Anti-CD70 antibody drug conjugates

#130
20150045573
2015-02-12

Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

#131
20150045282
2015-02-12

Compositions containing delta-9-THC-amino acid esters and process of preparation

#132
20150037268
2015-02-05

Niacin-peptide having skin whitening activity and use for same

#133
20150011458
2015-01-08

Selective caspase inhibitors and uses thereof

#134
20150005342
2015-01-01

Hepatitis C virus inhibitors

#135
20140336120
2014-11-13

Compositions and method for treatment of ischemic neuronal reperfusion injury

#136
20140336098
2014-11-13

Stabilized subtilisin composition

#137
20140303080
2014-10-09

N-acyldipeptide derivatives and their uses

#138
20140275522
2014-09-18

Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines

#139
20140248333
2014-09-04

Compositions and methods for inhibiting proteases

#140
20140243274
2014-08-28

Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

#141
20140243257
2014-08-28

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

#142
20140220122
2014-08-07

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

#143
20140147412
2014-05-29

Spiro compounds as Hepatitis C virus inhibitors

#144
20140105859
2014-04-17

MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

#145
20140094614
2014-04-03

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#146
20140087992
2014-03-27

Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof

#147
20140051623
2014-02-20

Bisphosphonate-prodrugs

#148
20140030221
2014-01-30

Macrocyclic inhibitors of flaviviridae viruses

#149
20140023616
2014-01-23

Macrocyclic inhibitors of flaviviridae viruses

#150
20140018303
2014-01-16

3-Amino-2-Hydroxy-4-Phenylbutanoyl-Valyl-Isoleucine, Preparation and Use Thereof

#151
20130344029
2013-12-26

Macrocyclic inhibitors of flaviviridae viruses

#152
20130309256
2013-11-21

Self-stabilizing linker conjugates

#153
20130267713
2013-10-10

Hepatitis C virus inhibitors

#154
20130267609
2013-10-10

Lipid dipeptide and gel

#155
20130203656
2013-08-08

Inhibitors of HCV NS5A

#156
20130066055
2013-03-14

NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF

#157
20130053303
2013-02-28

Compounds for enzyme inhibition

#158
20130041008
2013-02-14

Compounds for enzyme inhibition

#159
20130035297
2013-02-07

Compounds for enzyme inhibition

#160
20130029900
2013-01-31

Maytansinoid derivatives with peptide linker and conjugates thereof

#161
20130023460
2013-01-24

Amphiphilic linear peptide/peptoid and hydrogel comprising the same

#162
20130022573
2013-01-24

Macrocyclic inhibitors of flaviviridae viruses

#163
20120330019
2012-12-27

Hepatitis C virus inhibitors

#164
20120302815
2012-11-29

Multi-valent poly-Ubl chain inhibitors and methods of use

#165
20120282219
2012-11-08

Peptidomimetic protease inhibitors

#166
20120270813
2012-10-25

Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products

#167
20120253012
2012-10-04

Method for preparing lipopeptide compound

#168
20120253011
2012-10-04

Native chemical ligation at serine and threonine sites

#169
20120244122
2012-09-27

Peptides for the Treatment of HCV Infections

#170
20120238749
2012-09-20

INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME

#171
20120214732
2012-08-23

Inhibitors of the trypsin-like site of the proteasome and methods of use thereof

#172
20120208747
2012-08-16

Peptide for augmenting and expression of BDNF and pharmaceutical composition for prevention and treatment of neurodegenerative diseases including Alzheimer's disease or Parkinson's disease, comprising the same

#173
20120190816
2012-07-26

Asymmetric synthesis of peptides

#174
20120108515
2012-05-03

Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

#175
20120088762
2012-04-12

Compounds for enzyme inhibition

#176
20120064034
2012-03-15

Peptidomimetic protease inhibitors

#177
20120022228
2012-01-26

PURIFICATION OF AMPHOTERIC PRODUCTS, OR OF PRODUCTS LIABLE TO BE CONVERTED INTO AMPHOTERIC PRODUCTS

#178
20110311482
2011-12-22

Hepatitis C virus inhibitors

#179
20110294719
2011-12-01

Dipeptoid prodrugs and the use thereof

#180
20110286969
2011-11-24

DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS

#181
20110275784
2011-11-10

ASYMMETRIC SYNTHESIS OF PEPTIDES

#182
20110212964
2011-09-01

Modulators of pharmacokinetic properties of therapeutics

#183
20110183955
2011-07-28

2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators

#184
20110183913
2011-07-28

Lipid dipeptide and gel

#185
20110183413
2011-07-28

Biologically active C-terminal arginine-containing peptides

#186
20110172238
2011-07-14

Benzimidazole analogues for the treatment or prevention of flavivirus infections

#187
20110104063
2011-05-05

Flexibly labeling peptides

#188
20110077190
2011-03-31

Selective caspase inhibitors and uses thereof

#189
20110071040
2011-03-24

Mass- and property-tuned variable mass labeling reagents and analytical methods for simultaneous peptide sequencing and multiplexed protein quantification using thereof

#190
20110053858
2011-03-03

Heterocyclic peptide ketoamides

#191
20110021438
2011-01-27

Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide

#192
20110015371
2011-01-20

Inhibitors of interleukin-1 beta converting enzyme

#193
20100304363
2010-12-02

PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF

#194
20100298209
2010-11-25

COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION

#195
20100280221
2010-11-04

Peptide production and purification process

#196
20100273843
2010-10-28

Heterocyclic self-immolative linkers and conjugates

#197
20100260786
2010-10-14

Methods of treating drug-resistant cancers

#198
20100168032
2010-07-01

Smart Pro-Drugs of Serine Protease Inhibitors

#199
20100166706
2010-07-01

HCV NS-3 SERINE PROTEASE INHIBITORS

#200
20100145036
2010-06-10

Chemical linkers and cleavable substrates and conjugates thereof

#201
20100144649
2010-06-10

Compounds for enzyme inhibition

#202
20100144648
2010-06-10

Compounds for enzyme inhibition

#203
20100139716
2010-06-10

Prober cleaning block assembly

#204
20100137583
2010-06-03

Peptidomimetic protease inhibitors

#205
20100113770
2010-05-06

O-SUBSTITUTED HYDROXYARYL DERIVATIVES

#206
20100016631
2010-01-21

Method for the synthesis of peptides without solvent

#207
20100003216
2010-01-07

HCV NS-3 Serine Protease Inhibitors

#208
20090291952
2009-11-26

Modulators of pharmacokinetic properties of therapeutics

#209
20090286763
2009-11-19

AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF

#210
20090274656
2009-11-05

Hepatitis C virus inhibitors

#211
20090270618
2009-10-29

Phosphonyl ester conjugates as prodrugs

#212
20090239809
2009-09-24

Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products

#213
20090156509
2009-06-18

Tri-peptide Inhibitors of Serine Elastases

#214
20090149482
2009-06-11

Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment

#215
20090143248
2009-06-04

Biologically active C-terminal arginine-containing peptides

#216
20090082566
2009-03-26

Acyclovir-peptide analogs

#217
20090041791
2009-02-12

Heterocyclic self-immolative linkers and conjugates

#218
20080300191
2008-12-04

Protease inhibitors for coronaviruses and SARS-CoV and the use thereof

#219
20080293962
2008-11-27

Compounds of the N-acylamino amide family compositions comprising them and uses thereof

#220
20080281075
2008-11-13

Asymmetric synthesis of peptides

#221
20080279868
2008-11-13

Antibody-Drug Conjugates and Methods of Use

#222
20080214648
2008-09-04

Hiv Prodrugs Cleavable by Cd26

#223
20080207630
2008-08-28

2-aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitors (lap) modulators

#224
20080146642
2008-06-19

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

#225
20080108617
2008-05-08

Modulators of pharmacokinetic properties of therapeutics

#226
20080090862
2008-04-17

Isoquinoline derivatives as calpain inhibitors

#227
20080089842
2008-04-17

Flexibly labeling peptides

#228
20080070953
2008-03-20

Inhibitors of interleukin-1β converting enzyme

#229
20070293465
2007-12-20

Compounds for enzyme inhibition

#230
20070275900
2007-11-29

Prodrugs cleavable by CD26

#231
20070203072
2007-08-30

HCV NS-3 serine protease inhibitors

#232
20070161574
2007-07-12

HCV NS-3 serine protease inhibitors

#233
20070155801
2007-07-05

Advanced glycation end-product intermediaries and post-amadori inhibition

#234
20070142302
2007-06-21

Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux

#235
20070093426
2007-04-26

Histone H2A peptide derivatives and uses thereof

#236
20070037863
2007-02-15

Dipeptide phenyl ethers

#237
20060241057
2006-10-26

Peptidyl allyl sulfones

#238
20060211659
2006-09-21

Cosmetic compositions comprising N-acylamino amides

#239
20060172950
2006-08-03

Hepatitis C virus inhibitors

#240
20060166893
2006-07-27

2-hydroxytetrahydrofuran derivatives and use thereof as medicaments

#241
20060135438
2006-06-22

Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux

#242
20060111276
2006-05-25

Cidofovir peptide conjugates as prodrugs

#243
20060100160
2006-05-11

Amino acid derived prodrugs of propofol, compositions and uses thereof

#244
20060094718
2006-05-04

O-substituted hydroxyaryl derivatives

#245
20060089312
2006-04-27

Smart pro-drugs of serine protease inhibitors

#246
20050256030
2005-11-17

Heterocyclic self-immolative linkers and conjugates

#247
20050245511
2005-11-03

Novel compounds that inhibit tryptase activity

#248
20050222045
2005-10-06

Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments

#249
20050197299
2005-09-08

Peptidomimetic protease inhibitors

#250
20050187197
2005-08-25

Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof

#251
20050075293
2005-04-07

Dipeptide phenyl ethers

#252
20050049406
2005-03-03

Isotopically coded affinity markers 3

#253
20050043246
2005-02-24

Acyclovir-peptide analogs

#254
20050009755
2005-01-13

Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient